Company Info






  Home > Archived Webinars >

FDA Draft Guidance: EAP Program & Premarket/Postmarket Data Collection for PMA’s



 
Our Price: $395.00

Product Code: WB-7082
Qty:

Product Info
 
About the Product
Includes 1 hour and 20 minute Windows Media Video File and PowerPoint presentations for immediate download.


In April of 2014 the FDA has released a long-awaited draft guidance proposing a new program which provides an expedited approval pathway for high-risk medical devices that are intended to treat serious conditions whose needs are unmet by current technology. In addition to the Expedited Access Premarket Approval Application for Unmet Medical Needs for Life Threatening or Irreversibly Debilitating Diseases or Conditions or the “EAP” program, the FDA simultaneously released draft guidance entitled Balancing Premarket and Postmarket Data Collections for Devices Subject to PMA. The document outlines provisions specifying when data can be collected after product approval and FDA enforcement actions should these requirements not be met. It can be difficult for manufacturers to enroll patients in a trial once the product has been approved, therefore, the primary challenge for device companies will come when trying to meet the post-market data collection requirements in the FDA’s time frame.
  • In-depth overview of EAP program and eligibility criteria
  • Program benefits for industry and patients
  • Clarifying manufacturer post-approval data collect policies
  • Enforcement actions for non-compliance

Speaker:
Bethany J. Hills
Member of the Firm
Epstein Becker Green


Participants that will find this webinar most beneficial will be those involved in medical device companies. Job titles of attendees that will be most applicable for this session will be:

  • Regulatory Affairs
  • Pre-Market Approval
  • Post-Market Surveillance
  • Regulatory Submissions


Share your knowledge of this product. Be the first to write a review »